| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 43.3 | 48.0 |
| Profit before tax | 1.4 | 8.5 |
| Net income | 0.4 | 8.2 |
| EPS (diluted, $ a share) | $0.01 | $0.22 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -95.0% |
|---|---|
| Revenue, year on year | -9.6% |
| Operating margin | 5.7% |
10-Q filed with the SEC, NASDAQ: BTMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
biote Corp.: key numbers
- Share price
- $0.9603Close, Nov 16
- Sector
- Life Sciences
- Industry
- Medicinal Chemicals & Botanical ProductsSIC 2833
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from biote Corp.
All →biote Financial Results
biote Corp. reported third quarter 2026 revenue of $43.3 million, a 9.6% decrease year-over-year, primarily due to a decline in procedure revenue. The company maintained its full-year 2026 outlook, expecting revenue and Adjusted EBITDA to exceed $175 million and $25 million, respectively, despite slower-than-anticipated recovery in underlying demand.
- Term
- Q3 2026
“While a recent improvement in procedure volume provides early evidence of stabilization in underlying demand, our return to growth is progressing more slowly than anticipated. Our immediate priorities are to improve sales productivity and strengthen engagement with our trained practitioners as we work toward a return to revenue growth.”
Bob Peterson, Biote’s interim Chief Executive Officer
“Our strategic initiatives remain central to strengthening the business, and the foundational work completed over the past year provides a basis for improvement. As we move forward, we remain focused on enhancing the practitioner experience, increasing sales productivity, and supporting a return to growth.”
Bob Peterson, Biote’s interim Chief Executive Officer